{"id":"stapokibart-injection","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"While the precise mechanism of action for Stapokibart is not fully disclosed, it is known to interact with a biological pathway relevant to its therapeutic area, potentially leading to improved outcomes in patients with the targeted condition.","oneSentence":"Stapokibart injection is designed to target and modulate a specific pathway involved in the disease process, though the exact mechanism is not publicly detailed.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:36:33.981Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07483268","phase":"","title":"A Study of Stapokibart Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) .","status":"NOT_YET_RECRUITING","sponsor":"Chengdu Kangnuoxing Biopharma,Inc.","startDate":"2026-06","conditions":"CRSWNP","enrollment":600},{"nctId":"NCT07459556","phase":"","title":"A Prospective Study of Stapokibart Injection in Patients With Seasonal Allergic Rhinitis (SAR)","status":"NOT_YET_RECRUITING","sponsor":"Chengdu Kangnuoxing Biopharma,Inc.","startDate":"2026-03","conditions":"SAR","enrollment":400},{"nctId":"NCT07240376","phase":"NA","title":"Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Huazhong University of Science and Technology","startDate":"2025-11-25","conditions":"Non-Allergic Rhinitis With Eosinophilia Syndrome","enrollment":90},{"nctId":"NCT07210554","phase":"PHASE3","title":"Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid","status":"NOT_YET_RECRUITING","sponsor":"Chengdu Kangnuoxing Biopharma,Inc.","startDate":"2025-11-11","conditions":"Bullous Pemphigoid (BP)","enrollment":200},{"nctId":"NCT07073664","phase":"NA","title":"A Study Evaluating the Efficacy of Endoscope Ethmoid Infundibulum Expansion Surgery (EEIES) Combined With Stapokibart in the Treatment of Type 2 Chronic Rhinosinusitis","status":"ENROLLING_BY_INVITATION","sponsor":"China-Japan Union Hospital","startDate":"2025-04-21","conditions":"Chronic Sinusitis","enrollment":30},{"nctId":"NCT06424470","phase":"PHASE3","title":"Study on the Treatment of Prurigo Nodularis With Stapokibart Injection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2024-06-25","conditions":"Prurigo Nodularis","enrollment":200},{"nctId":"NCT06883552","phase":"PHASE2","title":"An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sichuan University","startDate":"2025-10-01","conditions":"Lung Cancer (NSCLC)","enrollment":21},{"nctId":"NCT06525597","phase":"PHASE2","title":"Study of Stapokibart Injection in Patients With Allergic Rhinitis","status":"RECRUITING","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2024-09-30","conditions":"Allergic Rhinitis","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Stapokibart injection","genericName":"Stapokibart injection","companyName":"Chengdu Kangnuoxing Biopharma,Inc.","companyId":"chengdu-kangnuoxing-biopharma-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Stapokibart injection is an antibody-based treatment being studied for various conditions, including Bullous Pemphigoid, Chronic Sinusitis, Lung Cancer, CRSWNP, and Prurigo Nodularis. It is being evaluated in a randomized, double-blind, placebo-controlled Phase III clinical study to assess its efficacy and safety.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}